Innovative approaches to prevent them include escalation strategies such as the combination of osimertinib and chemotherapy, applied in the FLAURA2 trial and the association of amivantamab, an EGFR-MET bispecific antibody, and lazertinib, a third-generation TKI, in previously untreated EGFR positive NSCLC patients as presented in the MARIPOSA trial [11,12]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.